JP2025504815A - 自己抗体媒介性疾患を有する患者を治療するための方法 - Google Patents

自己抗体媒介性疾患を有する患者を治療するための方法 Download PDF

Info

Publication number
JP2025504815A
JP2025504815A JP2024541851A JP2024541851A JP2025504815A JP 2025504815 A JP2025504815 A JP 2025504815A JP 2024541851 A JP2024541851 A JP 2024541851A JP 2024541851 A JP2024541851 A JP 2024541851A JP 2025504815 A JP2025504815 A JP 2025504815A
Authority
JP
Japan
Prior art keywords
subject
fcrn antagonist
cells
frequency
autoantibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504815A5 (https=
Inventor
ヴェルヘーセン ピーター
シップス マグダリーナ
ポルマン ロバート
ハートル マイケル
ジョリー パスカル
カルボ セバスティアン
マホ‐バイラント モード
Original Assignee
アルジェニクス ビーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルジェニクス ビーブイ filed Critical アルジェニクス ビーブイ
Publication of JP2025504815A publication Critical patent/JP2025504815A/ja
Publication of JP2025504815A5 publication Critical patent/JP2025504815A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024541851A 2022-01-17 2023-01-17 自己抗体媒介性疾患を有する患者を治療するための方法 Pending JP2025504815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263266852P 2022-01-17 2022-01-17
US63/266,852 2022-01-17
PCT/EP2023/050980 WO2023135321A1 (en) 2022-01-17 2023-01-17 Methods for treating patients with an autoantibody-mediated disease

Publications (2)

Publication Number Publication Date
JP2025504815A true JP2025504815A (ja) 2025-02-19
JP2025504815A5 JP2025504815A5 (https=) 2026-01-26

Family

ID=85036487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541851A Pending JP2025504815A (ja) 2022-01-17 2023-01-17 自己抗体媒介性疾患を有する患者を治療するための方法

Country Status (12)

Country Link
US (1) US20240369467A1 (https=)
EP (1) EP4466539A1 (https=)
JP (1) JP2025504815A (https=)
KR (1) KR20240134900A (https=)
CN (1) CN118556187A (https=)
AR (1) AR128284A1 (https=)
AU (1) AU2023207461A1 (https=)
CA (1) CA3241453A1 (https=)
IL (1) IL314322A (https=)
MX (1) MX2024007806A (https=)
TW (1) TW202333791A (https=)
WO (1) WO2023135321A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
TW202421195A (zh) * 2022-11-07 2024-06-01 比利時商阿根思公司 使用ｆｃｒｎ拮抗劑治療狼瘡性腎炎之方法
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025202714A1 (en) * 2024-03-26 2025-10-02 argenx BV Methods for treating primary sjogren's syndrome using fcrn antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法

Also Published As

Publication number Publication date
WO2023135321A1 (en) 2023-07-20
MX2024007806A (es) 2024-07-04
AR128284A1 (es) 2024-04-10
AU2023207461A1 (en) 2024-07-11
EP4466539A1 (en) 2024-11-27
CN118556187A (zh) 2024-08-27
CA3241453A1 (en) 2023-07-20
TW202333791A (zh) 2023-09-01
US20240369467A1 (en) 2024-11-07
IL314322A (en) 2024-09-01
KR20240134900A (ko) 2024-09-10

Similar Documents

Publication Publication Date Title
JP2025504815A (ja) 自己抗体媒介性疾患を有する患者を治療するための方法
Maho-Vaillant et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus
Thiel et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia
Gerrits et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia
Cines et al. The ITP syndrome: pathogenic and clinical diversity
Marquart et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE)
US20170190779A1 (en) Method for the treatment of multiple sclerosis
KR20040105740A (ko) 염증 치료제의 투여 방법
JP2020100631A (ja) 多発性硬化症の併用治療
US20240124573A1 (en) Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR)
CN111239415B (zh) 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
Di Muzio et al. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment
JP2024540865A (ja) 寛容化ナノ粒子による原発性胆汁性胆管炎（ｐｂｃ）の治療
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
HK40109266A (zh) 用於治疗患有自身抗体介导的疾病的患者的方法
Prelog et al. Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA)
WO2013049362A2 (en) Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
WO2022221527A1 (en) Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds
JP2008515983A (ja) ウイルス関連リンパ増殖性障害を処置または予防するための方法
Diehl et al. Schnitzler Syndrome With Extremely Elevated IL-6 Responds To Anti IL-1 Receptor Antagonist
Shiu Role of B Cells in Chronic Rejection of Human Kidney Transplants
KR20240134909A (ko) Il-18에 대한 항체를 포함하는 성인-발병성 스틸병 및 전신-발병성 소아 특발성 관절염에 대한 방법 및 치료
MARQUART* et al. Complement‐activating ability of leucocytes from patients with ‘qc complement factor I deficiency
Mohamed¹ et al. Desensitization across the HLA barrier in kidney transplantaion
Bryant The role of CXCR4/SDF-1 and VLA-4/VCAM-1 in migration of bystander-activated T cells: implications for rheumatoid arthritis

Legal Events

Date Code Title Description
RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260115